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Abstract: The pediatric population is continually at risk of developing infectious and inflammatory
diseases. The treatment for infections, particularly gastrointestinal conditions, focuses on oral or
intravenous rehydration, nutritional support and, in certain case, antibiotics. Over the past decade,
the probiotics and synbiotics administration for the prevention and treatment of different acute
and chronic infectious diseases has dramatically increased. Probiotic microorganisms are primarily
used as treatments because they can stimulate changes in the intestinal microbial ecosystem and
improve the immunological status of the host. The beneficial impact of probiotics is mediated by
different mechanisms. These mechanisms include the probiotics’ capacity to increase the intestinal
barrier function, to prevent bacterial transferation and to modulate inflammation through immune
receptor cascade signaling, as well as their ability to regulate the expression of selected host intestinal
genes. Nevertheless, with respect to pediatric intestinal diseases, information pertaining to these
key mechanisms of action is scarce, particularly for immune-mediated mechanisms of action. In the
present work, we review the biochemical and molecular mechanisms of action of probiotics and
synbiotics that affect the immune system.
Keywords: probiotics; pediatric gastrointestinal infection; mechanism of action; intestinal microbiota;
immune system
1. Introduction
Pediatric intestinal diseases comprise a variety of clinically important conditions, such as
infectious diseases (acute diarrhea, antibiotic-associated diarrhea (AAD), Clostridium difficile-associated
diarrhea, and Helicobacter pylori infection), and necrotizing enterocolitis (NEC), as well as some
non-communicable chronic diseases, including inflammatory bowel diseases (IBD) (ulcerative colitis
and Crohn disease) and cystic fibrosis.
Pediatric infectious diseases are the most important illnesses in children, especially in preschool
centers [1]. Children who go to daycare centers are at a 2.2–3.5-fold greater risk of developing
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gastrointestinal infections than children who stay at home [2,3]. In addition, studies have suggested
that poor hygiene is related to the development of such infections [4,5].
Acute infectious diarrhea and AAD are the two primary manifestations of gastrointestinal
pediatric infections. Acute diarrhea is frequently originated through viral infection, with rotavirus and
Norwalk virus infections being common causes of gastroenteritis in children. In addition, important
infectious bacteria are implicated in day care-associated gastrointestinal disorders, such as Escherichia
coli, Salmonella sp., Campylobacter jejuni, Clostridium difficile and Helicobacter pylori [6–9].
In developing countries, more than 500,000 people die annually due to diarrhea associated with
rotavirus gastroenteritis. In Europe, almost every child will have experienced an episode of rotavirus
gastroenteritis, and one in 54 will need hospitalization [10].
AAD is known to disrupt the gastrointestinal microbiota that marks in a variety of medical
symptoms. The AAD incidence in children in primary health services is approximately 10% [11,12].
C. difficile infections primarily occur in immunocompromised hosts and represent serious infection
for which the primary treatment is antibiotic therapy. In fact, C. difficile infection is the leading cause
related to antimicrobial therapy, accounting for nearly 15–25% of all AAD episodes [13].
Additional pediatric intestinal diseases that are frequently associated with intestinal dysbiosis
include: NEC, a health condition that is principally appreciated in premature infants with bowel
undergo necrosis [14]; ulcerative colitis, a chronic IBD of unknown etiology that is characterized by
acute exacerbations of intestinal complications, followed by remissions; Crohn’s disease, a systemic
disorder in which the development of host genetic susceptibility represents an important etiological
factor [15]; and cystic fibrosis, a fatal genetic disease without cure, affecting the digestive system and
lungs with some typical complications, such as difficulty digesting fats and proteins, malnutrition and
vitamin deficiencies resulting from an inability to absorb nutrients, chronic infections and aberrant
inflammation [16].
The current treatment for pediatric infectious diseases focuses on oral or intravenous rehydration,
nutritional support, and in some cases, antibiotics. The new therapeutic alternatives, for example
antiemetics, antidiarrheal agents, and probiotics are often proposed. Oral rehydration therapy prevents
only related dehydration [17], but does not affect the frequency of bowel movements, diarrheal
duration, or intestinal barrier function [18,19]. Indeed, to better limit and heal intestinal damage, new
treatment alternatives are required.
Alteration to the gut microbiome through the administration of beneficial microbes, typically
referred to as probiotics, is an active area of investigation [15,20–22]. Probiotics are defined as “live
microorganisms that confer a health benefit to the host when administered in adequate amounts,
although dead bacteria and bacterial molecular components may also exhibit probiotic properties” [22].
Recent reviews and meta-analyses have suggested an effect of probiotics in the treatment and
prevention of gastrointestinal and upper respiratory infections in children [23–30]. Probiotics appear
to have a beneficial impact in treating acute infectious diarrhea and reducing AAD. However, the
potential advantage of probiotics in the prevention of traveler’s diarrhea and C. difficile-associated
diarrhea, as well as the adverse effects in H. pylori eradication, NEC, IBD, and cystic fibrosis remain
unclear, the principal reason being that the effects tend to be strain-specific [3,31–33].
A prebiotic is a non-viable food component that confers a health benefit to the host and is
associated with the modulation of the intestinal microbiota. Using prebiotics and probiotics in
combination is often described as synbiotics [34,35].
The administration of probiotics for the prevention and treatment of a variety of pediatric
infectious diseases has received increasing attention worldwide. Many scientific reports from
different societies, such as the European Society of Pediatric Gastroenterology, Hepatology and
Nutrition (ESPGHAN) [24], the American Academy of Pediatrics [36], the World Gastroenterology
Organization [37], and the Canadian Pediatric Society [38] have indicated the benefits of probiotics,
supporting recommendations for the use of probiotics to treat acute gastroenteritis and for the reduction
of AAD. Several important mechanisms that underlie the observed beneficial effects of probiotics
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include secretion of antimicrobial substances, competitive adherence to the mucosa and epithelium,
strengthening of the gut epithelial barrier, and modulation of the immune system [22,23,32]. Probiotic
effects that are mediated through these mechanisms are an important issue that needs to be addressed.
In addition, pro-inflammatory transcription factors, cytokines, and apoptosis-related enzymes can
also be affected by probiotic strains. However, information on the mechanism of action of these
effects, which are mediated by probiotics, is scarce, especially details related to the modulation of the
immune system.
Therefore, the present review was conducted to investigate what is known from published
research on the immune-mediated effects of probiotics and synbiotics in the prevention and treatment
of pediatric intestinal diseases, with a special focus being placed on the mechanisms of action related
to immune system modulation.
2. Materials and Methods
A comprehensive search of the relevant literature was performed using electronic databases,
including MEDLINE (PubMed), EMBASE, and the Cochrane Library. We searched for scientific
articles published between 2009 and 2017 in English in MEDLINE through PubMed. We used
the MeSH terms “probiotics” and “synbiotics” combined with “infection” “pediatrics” and
“gastrointestinal diseases”. We evaluated the results that were obtained using the following equation
search: ((“infection”[MeSH Terms] OR “infection”[All Fields]) AND (“pediatrics”[MeSH Terms]
OR “pediatrics”[All Fields] OR “pediatric”[All Fields])) AND ((“probiotics”[MeSH Terms]
OR “probiotics”[All Fields] OR “probiotic”[All Fields]) OR (“synbiotics”[MeSH Terms] OR
“synbiotics”[All Fields] OR “synbiotic”[All Fields])). Our search yielded 211 articles, 31 of which
were selected that specifically inform on probiotic mechanisms of action. Additionally, we searched
the reference lists of the included articles for potential relevant literature.
3. Results and Discussion
3.1. Major Clinical Effects and Related Mechanisms of Action of Probiotics in Pediatric Intestinal Diseases
3.1.1. Gastrointestinal Infections
One thousand and sixty-two preschool children were enrolled in a double-blind, randomized,
controlled study to test the effects of L. casei rhamnosus, L. rhamnosus T cell-1, multiple probiotics,
and a placebo over 3 and 7 month periods [39]. Single strain probiotic supplementation significantly
decreased the incidence of bacterial infections. Nevertheless, the multiple probiotic supplements
did not show any effect. The only strain that decreased infectious disease at 3 months was L. casei
rhamnosus. The authors hypothesized that the results were mediated through the action of lactobacilli
species, as they can affect antigen-specific IgG1/IgG2 antibodies and cytokine responses and can also
stimulate dendritic cells (DC) and produce a Th1 response [39].
L. rhamnosus GG strain is the most evaluated probiotic on pediatric population, alone or in
combination with prebiotics or vitamins. A prospective, randomized, double-blind, placebo-controlled
trial was performed to test the L. rhamnosus GG administration during 3 months in 281 children.
The L. rhamnosus GG treatment was only successful only in the prevention of upper respiratory tract
infections in children who attended primary health services [40]. This study showed no significant
effect of the L. rhamnosus GG treatment with respect to the observed number of gastrointestinal
infections and the number of diarrhea and vomiting episodes. In contrast, using a similar methodology
in hospitalized children, Hojsak et al., 2010 observed that a L. rhamnosus GG treatment significantly
reduced the gastrointestinal infections, vomiting, and diarrhea episodes [41]. In both studies,
the authors only mentioned a few documented effects of probiotics related to antimicrobial properties
and enhancement in mucosal barrier and their immunomodulatory action.
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An immunological approach was performed in 124 children (82 infected with rotavirus and 42
with cryptosporidial diarrhea) that evaluated the L. rhamnosus GG effects on immune response and
intestinal permeability. In the L. rhamnosus GG group less children had repeated diarrheal events and
impaired intestinal function. Moreover, children that received L. rhamnosus GG have an increase in
IgG levels post-intervention. L. rhamnosus GG administration exhibited a significant enhancement
in intestinal permeability in children with cryptosporidial diarrhea [42]. The authors stated that the
mechanism by which probiotics produce an immunomodulatory action is not completely understood
and might be related to the modulation of immune responses (innate and adaptive), increasing serum
IgG and secretory IgA to enteric pathogens, including Salmonella typhi and rotavirus [42].
Another study with L. rhamnosus GG was performed in 90 hospitalized children, and they received
L. rhamnosus GG plus vitamin B, vitamin C, and zinc or placebo. The consumption of a combination
of L. rhamnosus GG and micronutrients was effective in reducing the incidence of gastrointestinal
infections and the length of hospitalization compared to placebo [43]. Furthermore, the duration and
severity of symptoms were reduced [43]. No mechanism of action was reported to be associated with
the observed effects.
The last L. rhamnosus GG study was a follow-up study that was conducted for 3 and 5 years in
109 and 96 children, respectively. Children received hydrolyzed protein formulas with L. rhamnosus
GG, and the primary expected result (the decrease of the incidence of acute gastroenteritis mediated
through the action of L. rhamnosus GG) was not observed at the analyzed time-points [44].
Studies on the administration of L. rhamnosus GG have shown contradictory results. In some
studies, probiotic treatment decreased the frequency and gravity of gastrointestinal diseases, and in
others, an effect was not observed. It is important to mention that the administration doses and time
interventions were different in these studies, and future studies should be standardized to assess a
potential successful result. Regarding the mechanism of action, the primary mechanism proposed for
L. rhamnosus GG was the modulation of the innate and adaptive immune system, but this was mostly
based on speculation.
The gastrointestinal effects and antibiotic sensitivity of L. salivarius CECT5713 were analyzed in
80 6-month-old children during 3 and 6 months of intervention. A probiotic treatment decreased the
frequency of diarrhea and respiratory infections compared with placebo group [45]. Fecal concentration
of butyric acid has augmented in L. salivarius CECT5713 group, this acid reduce the colonic pH and
increase the peristaltic movements, promoting an advantageous environment for commensal bacteria.
The authors observed a lower frequency of diarrhea in L. salivarius CECT5713 group, and they related
this finding to in vitro assays, reporting on the production of antimicrobial compounds through
L. salivarius CECT5713 action [45].
In 2012, 215 infants were enrolled to test the effects of L. fermentum CECT5716 plus
galactooligosaccharides (GOS) during 6 months. L. fermentum administration was useful for the
prevention of gastrointestinal infections in infants [46], increasing bifidobacteria and lactobacilli.
The production of short chain fatty acids and IgA concentrations did not change during the study.
The authors linked those changes in bifidobacteria and lactobacilli with the reductions in the number
of gastrointestinal episodes observed in L. fermentum CECT5716 plus GOS group [46].
A follow-up study that lasted 3 years observed similar values of growth, frequency of infectious
and non-infectious diseases in children that received the L. fermentum CECT5716 formula compared
with placebo [47]. The proposed mechanism of action was the innate response activation through the
L. fermentum CECT5716 plus GOS, although no changes in fecal IgA were detected [47]. The effects of
L. salivarius CECT5713 were mediated through butyric acid production, and a L. fermentum CECT5716
plus GOS treatment appeared to produce changes in the intestinal microbiota.
Regular calcium content plus L. casei CRL431 or L. reuteri DSM17938 treatments were tested in 494
children. The frequency of diarrhea episodes was significantly lower in the L. reuteri group compared
with the placebo group [48]. Similar results were shown in children supplemented with fermented
milk with killed-L. paracasei CBA L74 or placebo for 3 months on a daily basis. The probiotic treatment
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decreased the number of episodes of acute gastroenteritis compared to placebo [49]. These effects
were mediated by an augment of immunity peptides. Moreover, to their antimicrobial character these
peptides regulate the T cells activity, DC, macrophages, monocytes, and neutrophils, as well as the
production of secretory IgA, in the killed-L. paracasei CBA L74 group [49].
The administration of L. casei DN-114 001 was effective in decreasing gastrointestinal infections
in 638 3–6-year-old children in daycare centers/schools [50]. The authors recognized that this trial
studied a precise probiotic strain, dose, and age group, and their findings cannot be generalized for
other species or consequences without explaining a mechanism of action.
Conversely, several studies did not show clinical effects of probiotic strains over gastrointestinal
infections. L. reuteri DSM 17,938 was administered in children, no differences were found between the
probiotic and placebo groups [51]. In addition, healthy children over 4 months old were investigated
in a study consisting of a 3-month product consumption period and a 1-month follow-up period
with a fermented milk containing L. casei CNCM I-1518 [52]. These negative results were related to
the administered doses (low doses), the strain specificity, and the intervention time of each study.
Unfortunately, none of these studies evaluated the mechanism of action of the probiotics.
Members of the genus Bifidobacterium are another important group of probiotic species. B. lactis
B94 plus inulin were tested in 79 children with diarrhea. Compared with 77 children in the placebo
group, the synbiotic treatment reduced the length of diarrhea, and this reduction was most pronounced
in the Rotavirus diarrhea cases [53]. The number of diarrheal stools on the third day was significantly
smaller in the synbiotic group. Although the reduction in stool frequency on the third day was more
pronounced, the number of diarrheal stools on the second day was also significantly smaller in the
synbiotic group [53]. The authors stated that the presented effects were related to inulin administration.
Although prebiotics are generally well tolerated, they can cause bloating, abdominal pain, and diarrhea
when taken in excessive amounts. In this study, the patients were given 900 mg of inulin, and no
symptoms of discomfort were observed [53]. Further studies in this field are still required to reveal the
actual mechanism of action in a synbiotic treatment.
In contrast, with the previous study, the results of B. animalis subsp. lactis administration was
tested in 727 children. The ingestion of probiotic strain failed to prevent gastrointestinal infections in
children [54]. In another double-blind, placebo-controlled study with 109 children who were randomly
divided into the receiving group being administered the same probiotic strain and the placebo group,
the probiotic administration failed in decreasing the reported gastrointestinal symptoms or fever [55].
The authors hypothesized that xylitol, present in the administered tablets, might perform as a prebiotic
ingredient to influence the gut colonization of probiotic strain.
Finally, a recent study was conducted in 290 infants that received a mixture of B. animalis subsp.
lactis and L. rhamnosus GG for a 6-month intervention period. The outcomes revealed that the mixture
administration did not decrease the absence of children from primary health services [3]. It is important
to mention that the use of products containing other probiotics and prebiotics were not prohibited
during the study [3]. A potential immunoprotective effect of breastfeeding, might thus have reduced
the study power. Molecular mechanisms of action were not listed in the study.
Several probiotics strains were administered in the aforementioned studies, but it appears that the
intervention time and method used to evaluate the primary outcome are the most important variables
to obtain promising results. L. rhamnosus GG was the most assessed strain, showing contradictory
results in the incidence and severity of gastrointestinal diseases. The proposed mechanism of action of
this bacterium was the modulation of the innate and adaptive immune system. Other strains, such as,
L. salivarius CECT5713, act through butyric acid production, and an L. fermentum CECT5716 plus GOS
treatment generated a number of changes in the intestinal microbiota. In addition, some studies did
not show clinical effects of the probiotic strains over gastrointestinal infections, even the strains belong
to the Lactobacillus or Bifidobacterium genera. Table 1 shows the most relevant information regarding
selected studies of children with probiotic approaches.
Nutrients 2018, 10, 42 6 of 20
Table 1. Prevention and treatment of pediatric gastrointestinal infections with probiotics.
Reference Participants Probiotic Strain/Treatment Time Primary Outcome
Song-Lin et al., 2009 [39] 986 children L. casei rhamnosus, L. rhamnosusT cell-1, and a mixture of strains 7 months
L. casei rhamnosus reduced respiratory infections, whereas multiple
probiotic supplementation reduced the gastrointestinal disease.
L. rhamnosus T cell-1 decreased the incidence of bacterial infection
at 7 months
Hojsak et al., 2010 [40] 281 children L. rhamnosus GG 3 months Only prevention of upper respiratory tract infections
Hojsak et al., 2010 [41] 742 children L. rhamnosus GG 1 week
L. rhamnosus GG treatment significantly reduced the risk for
gastrointestinal infections, vomiting, and episodes of
gastrointestinal infections
Kulandaipalayam et al.,
2014 [42] 124 children L. rhamnosus GG 1 month
L. rhamnosus GG decreased diarrheal episodes and restored normal
intestinal permeability
Bruzzese et al., 2016 [43] 90 children L. rhamnosus GG plus vitaminsB, C and zinc 2 weeks
Treatment reduced incidence of gastrointestinal infections and
length of hospitalization
Maldonado et al., 2010 [45] 80 children L. salivarius CECT5713 6 months L. salivarius CECT5713 decreased incidence of diarrhea andrespiratory infections
Maldonado et al., 2012 [46] 215 children L. fermentum CECT5716 plusGOS 6 months
Synbiotic administration prevented community-acquired
gastrointestinal infections in infants
Maldonado et al., 2015 [47] 91 children L. fermentum CECT5716 plusGOS 3 years follow-up All variables measured were similar compared with placebo
Scalabrin et al., 2017 [44] 109 children L. rhamnosus GG 5 years follow-up A decrease in the incidence of acute gastroenteritiswas not detected
Agustina et al., 2012 [48] 494 children RCC plus L. casei CRL431, orRCC plus L. reuteri DSM17938 6 months
Incidence of all reported diarrhea and diarrhea incidence in
children with a lower nutritional status were significantly lower
in the L. reuteri group
Corsello et al., 2017 [49] 126 children L. paracasei CBA L74 3 months Probiotic treatment decreased the number of episodesof acute gastroenteritis
Merenstein et al., 2010 [50] 638 children L. casei DN-114 001 3 months L. casei DN-114 001 decreased gastrointestinal infections
Wanke et al., 2012 [51] 106 children L. reuteri DSM 17938 1 week No effects
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Table 1. Cont.
Reference Participants Probiotic Strain/Treatment Time Primary Outcome
Prodeus et al., 2016 [52] 599 children L. casei CNCM I-1518 3 months No effects
Islek et al., 2014 [53] 156 children B. lactis B94 plus inulin 1 week Synbiotic treatment decreased the duration of diarrhea
Hoksak et al., 2015 [54] 727 children B. animalis subsp. lactis BB-12 1 week No effects
Taipale et al., 2016 [55] 67 children B. animalis subsp. lactis BB-12 2 years follow-up No effects
Laursen et al., 2017 [3] 290 children B. animalis subsp. lactis and L.rhamnosus GG 6 months No effects
Abbreviations: GOS, galactooligassacharides; mixture of strains, three bifidobacteria, seven lactobacilli, S. thermophilus, and E. faecium; RCC, regular calcium content.
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3.1.2. Antibiotic-Associated Diarrhea (AAD)
The AAD happens when antibiotics disrupt the natural ecology in the mucosal tract, causing the
increase of pathogens bacteria. The symptoms of AAD include abdominal pain and extensive bowel
movements [56].
A recent study was performed in 97 children to test the effectiveness of L. reuteri DSM 17938 in
the prevention of AAD. The probiotic administration did not change the frequency or rigorousness of
AAD [57]. A weakness of this study was the lack of fecal analysis to confirm compliance and survival
of the probiotic administration.
Twenty-three studies with 3938 participants were included in a systematic review of the treatment
of AAD with probiotics. Analyzed trials included treatment with either Bacillus spp., Bifidobacterium
spp., Clostridium butyricum, lactobacilli, Lactococcus spp., L. cremoris, Saccharomyces spp., or Streptococcus
spp., alone or in combination. Two strains (L. rhamnosus or S. boulardii) may be the most recommended.
In the case of immunocompromised or debilitated children, the use of probiotics needs a rigorous
evaluation to assess patient safety [56].
Finally, the authors gave some evidence that proposes a defensive effect of probiotics in AAD.
For that reason, further well-designed studies are desired to adjust the safety of probiotics as a
treatment option for AAD. Currently, probiotic administration in the pediatric population with AAD is
avoided. No specific mechanisms of action have been addressed in most of studies related to treatment
of ADD with probiotics.
3.1.3. Clostridium difficile-Associated Diarrhea
Clostridium difficile-related diseases include severe diarrhea, colitis, and pseudomembranous
colitis. The treatment is costly, and probiotics have been suggested as a cheap strategy to both prevent
and treat C. difficile-associated diarrhea. In the last systematic review, a total of 31 studies with
4492 participants were discussed regarding this issue. The administration of probiotics was safe and
effective for preventing C. difficile-associated diarrhea [58]. In contrast to AAD, probiotic administration
seems to be safe, well tolerated, and indicated as coadjuvant therapy in C. difficile-associated diarrhea.
In addition, immunocompromised or severely debilitated patients as a risk group always require
a risk-benefit evaluation. Further clinical trials are needed to elucidate the mechanisms by which
probiotics prevent C. difficile-associated diarrhea [58].
3.1.4. Helicobacter pylori Gastritis and Peptic Ulcer
Helicobacter pylori is accepted as a main etiological issue in the pathogenesis of gastritis and peptic
ulcer disease. In pediatric population, the H. pylori eradication has a failure percentage of more than
30%, due to reduced compliance, antibiotic resistance, and the incidence of adverse events. A study
was performed in sixty children with H. pylori who treated with H. pylori eradication treatment protocol
(omeprazole + amoxycillin + furazolidon or other antibiotic), and randomly divided to receive either
probiotic mixture or placebo. The probiotic treatment with L. acidophilus, L. rhamnosus, L. bulgaricus,
L. casei, S. thermophilus, B. infantis, and B. breve increased the H. pylori eradication ratio. Moreover,
it was the most effective treatment in lowering the frequency of nausea, vomiting and diarrhea [59].
The authors argued that the observed probiotic effects might have been mediated by Lactobacillus
strains that interfered with the activity of H. pylori through preventing its adherence to epithelium and
incapacitating its primary virulence factor, urease enzyme.
Developing countries have a higher prevalence of H. pylori infections. Therefore, new non-invasive
therapies are preferred, among which the H. pylori stool antigen testing is included. Twenty-eight
children with a positive stool test for H. pylori were randomized in a clinical trial, with individuals
receiving S. boulardii or placebo for one month. The probiotic administration reduced the mean amount
of antigen present during the study, but was not competent of causing the H. pylori abolition when
used as a mono-therapy [60].
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These results contrast with another study in which children who had biopsy-proven H. pylori
infections were randomly divided to receive the H. pylori eradication treatment protocol plus B. lactis
B94 and inulin for 14 days, and the standard therapy alone. The abolition ratio were similar in both
groups. In addition, the synbiotic do not show advantage compared with standard therapy conducted
alone [61]. The limitations of this study were that H. pylori culture and antibiotic susceptibility tests
were not performed, B. lactis B94 colonization in the feces was not evaluated, and the authors stated
that the sample size was relatively small. In addition, the authors only mention and speculate that
the probiotic effects might be achieved by the production of short-chain fatty acids, autolysins, mucin,
and bacteriocins and/or by the binding of some specific strains to the same glycolipid receptors as
H. pylori [61].
Recently, Feng et al., 2017 described some important results from 29 trials involving 17 different
probiotic treatments. When the standard therapy was accompanied with a probiotic strain,
the eradication of H. pylori was successful. The most identified strain in the aforementioned effect
was L. casei as mono-therapy, as a multi-strain therapy B. infantis, B. longum, L. acidophilus, L. casei,
L. plantarum, L. reuteri, L. rhamnosus, L. salivarius, L. sporogenes, and S. thermophilus was the best in
reducing the incidence of diarrhea. Indeed, probiotic ingestion is suggested to supplement H. pylori
eradication treatment protocol in pediatric population, and the effectiveness of this therapy is related
with the particular probiotic administration. Finally, the proposed mechanism of actions for H. pylori
eradication include the following: increased competition with H. pylori to bind surface receptors
of intestinal epithelial cells; inhibiting adhesion of H. pylori to mucosa; altering the inflammatory
factors expression; strengthening of the intestinal mucosa barrier; and secretion of antimicrobial
substances [62].
Taking into consideration the current literature, AAD is the only pathology for which probiotics
should be avoided. Likewise, the mechanism of action and their clinical effects requires further
investigation. Moreover, the administration of probiotics was a safe coadjuvant therapy in the case of
C. difficile-associated diarrhea.
3.1.5. Necrotizing Enterocolitis
Necrotizing enterocolitis (NEC) is a disturbing inflammatory disorder that primarily occurs in
preterm neonates and causes high mortality rates (20–30%) [63]. In fact, NEC is the leading cause of
death from gastrointestinal disease in premature newborns with low birth weight (LBW). Probiotics
were recently reported to be beneficial to infants with NEC. Indeed, several meta-analyses indicated
that probiotics reduce the risk of NEC and all causes of mortality, but not of sepsis, in preterm
infants [14]. Such a treatment has also been shown to decrease mortality and days of hospitalization
and to increase the effectiveness of exclusive enteral nutrition in the days following treatment [64,65].
The pathogenesis of NEC is still discussed, although besides prematurity and LBW, known risk
factors include early formula feeding and an altered intestinal microbiota [66]. In 2010, Alfaleh et al.,
2010 established that enteral supplementation with probiotics reduces the risk of severe NEC and
mortality in preterm newborns [67]. Twenty-four trials showed that enteral probiotic supplementation
significantly decreased the incidence of severe NEC and mortality. Probiotic preparations containing
either Lactobacillus alone or in combination with Bifidobacterium were found to be positive.
Lactobacillus rhamnosus HN001 is a Gram-positive bacterium which is beneficial for inflammatory
diseases treatment due to its probiotic actions [66]. Though the specific mechanisms of action of that
probiotic are still unknown related to NEC, different studies, with strains such as L. rhamnosus HN001,
have reported that the microbial DNA receptor Toll-like receptor-9 (TLR9) can be activated, which has
been described as a potential therapeutic target. Thus, L. rhamnosus HN001 is capable of attenuating
NEC in in vitro studies through via microbial DNA (Lr-DNA). Such protection requires activation of
TLR9, which has no evidence of toxicity [68].
Lactobacillus reuteri is a probiotic bacterium which has also been studied with the aim to prevent
NEC. This probiotic inhibits enteric infections and controls the immune system. L. reuteri produces
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a potent antibacterial compound that inhibits the growth of microorganisms and modulates tumor
factor necrosis alpha (TNF-α) synthesis from bacterial lipopolysaccharide (LPS)-activated monocytoid
cells [69–71]. The human-derived L. reuteri strains DSM17938, ATCC PTA4659, ATCC PTA 5289,
and ATCC PTA 6475 decreased the LPS induced-inflammation in small intestinal epithelial cells and
in the ileum of neonatal rats [71]. Afterwards, Liu et al. (2012) reported that those L. reuteri strains
reduced bowel inflammation by downregulating interleukin (IL)-6, TNF-α, TLR4, and nuclear factor
κ-B (NF-κB) and upregulating IL-10 in newborn rats with NEC. In addition, L. reuteri led to a decrease
in intestinal TLR4, TNF-α and IL1β in the experimental model, demonstrating a potential therapeutic
profile of this probiotic in the prevention of NEC [72].
With respect to NEC, it has been described that a live probiotic from diet might remain effective
at reducing the translocation of pathogens in a short-term animal model [73]. Copeland et al. (2009)
studied whether a live probiotic diet, such as L. lactis, could have the same effects in a long-term
neonatal rabbit model. The fortified probiotic diet produced a significant reduction in translocation
of Enterobacter to the liver and the colonization in the stomach and lungs was also lower in rabbit
pups. Moreover, colonization or translocation of the probiotic outside of the gastrointestinal tract was
prevented by the diet and rabbits tested positive for L. lactis in the cecum, exhibiting the ability of this
probiotic to survive the transit to the colon [66].
Immunity and subsequent resistance to enteric pathogens of gut predominate during initial
infancy and do not appear during any other stage of life [74]. Thus, infections caused by enteric
bacterial pathogens are one of the most important causes of severe infantile diarrhea. Likewise, it has
been reported that probiotic treatments, such as Lactobacillus acidophilus, attenuate bacterial-mediated
intestinal injury and inflammation, which enhanced the host defense against enteric bacterial
infection [75]. Foye et al. (2012) showed that early inoculation of the probiotic L. acidophilus might
improve host-protective immunity to enteric bacterial pathogens by means of the TGF-β (transforming
growth factor b) response. Thus, the anti-inflammatory effects were triggered through decreasing
Smad 7 expression, allowing TGF-β to activate IκB-α and lower NF-κB accumulation [76]. An in vivo
study was carried out to assess the probiotic properties of L. acidophilus, a prebiotic, inulin or both
(synbiotic) on pathogen-induced inflammatory reactions in neonatal mice. Mice were inoculated
twice per week for 4 weeks with L. acidophilus, inulin, or the synbiotic and were challenged with the
pathogenic bacterium C. rodentium at 5 weeks. They observed that L. acidophilus and/or prebiotic inulin
consumption reduced C. rodentium-induced early morbidity and inflammation in mice. In addition,
an in vitro study was carried out in mice. The intestinal epithelial cell line CMT-93 was treated with
C. rodentium to determine changes in NF-κB and Smad (similarity to the Drosophila gene Mothers Against
Decapentaplegic (Mad)) 7 levels. Thus, NF-κB was activated at 60 min post-C. rodentium infection,
as indicated by IκB-α degradation in CMT93 cell line. These findings indicated that TNF-α production
reveals that C. rodentium bacteria-induced NF-κB activation and Smad 7 response was associated with
the pro-inflammatory cytokine production in intestinal epithelial cells. This study supports the fact that
probiotics are capable of promoting host-protective immunity and of attenuating C. rodentium-induced
bowel inflammation through mechanisms that affect NF-κB and Smad 7 expression [76].
Probiotics reduce the pro-inflammatory status by immunomodulation and by protecting tissues
against microbial infection [77], and their mechanism of action consists of modifying the production of
cytokines in diverse cell populations. Lactobacillus rhamnosus GG is a probiotic strain that is commonly
integrated into fermented products. In rats, it has been demonstrated to decrease LPS-induced
systemic inflammation [78]. Accordingly, it has been described that L. rhamnosus GG provokes IL-4,
IL-10, and urocortin expression and inhibits LPS-induced TNF-α in trophoblast cells from human
term placenta. Thus, these findings support the immunomodulatory effect of probiotics in human
placenta [79,80]. Another study reported that the probiotic L. rhamnosus GG diminishes Campylobacter
jejuni infection and butyrate transporter and receptor are expressed in differentiated Caco-2 cell
monolayers. The butyrate protection against C. jejuni adhesion are correlated to the existence of HCAR2
and SLC5A8, which are a receptor and transporter of butyrate, respectively. Moreover, the L. rhamnosus
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GG exerts the same effects [81]. Concerning inflammatory cytokine production, other described
mechanisms include TGF-β/SMAD and NF-κB signaling pathway. The probiotic L. acidophilus was
reported to decrease Salmonella-induced NF-κB activation in human intestinal Caco-2 cells. Moreover,
TNF-α and IL-8 expression was significantly lowered and TGF-β1 and MIR21 levels were higher in
L. acidophilus-treated cells compared with cells infected with only Salmonella [82]. In contrast, the levels
of SMAD7, which it is a target of MIR21, were lower in cells treated with L. acidophilus or synbioticaly
with inulin. Indeed, consistent with TGF-β1/MIR21 and SMAD7 expression, transcriptional activity
of SMAD3/4 was significantly increased in cells treated with L. acidophilus or synbiotics. This suggests
that TGF-β1/MIR21 expression might be useful as a marker to assess the anti-inflammatory effects of
different Lactobacillus strains and that probiotics may be a new treatment approach for inflammation
due to Salmonella infection [82].
Finally, Rojas et al., 2012 evaluated the use of prophylactic probiotics to prevent death and
nosocomial infections in preterm newborns. Although they observed a 40% decrease in the incidence
of NEC in the group treated with probiotics, they did not observe a primary outcome of the study.
However, it may be clinically relevant and it is consistent with others studies that assessed NEC [83].
In summary, animal studies appear to be more widely used in the evaluation of potential
mechanisms of actions for probiotics. The results from these studies show that probiotic treatment
might improve inflammatory status by immunomodulation, treating and reducing NEC. Further
analyses are required in human trials to ensure that no adverse effects occur from the treatment of
probiotics. Table 2 shows the primary information relating to the mechanism of action in NEC.
3.1.6. Inflammatory Bowel Diseases
Ulcerative colitis and Crohn’s disease are the primary manifestations of IBD. Recently,
we published a review that focuses on the treatment of chronic diseases in in vitro, animal, and
human studies after the probiotics treatment. The use of probiotic strains seems to be potentially well
tolerated, effective, and safe in patients with IBD. Indeed, probiotics improved clinical symptoms
in patients with mild to moderate active ulcerative colitis; the results in Crohn’s disease are unclear.
Some probiotics and their supernatants act by decreasing the pro- and inflammatory cytokines gene
expression by the modulation of TLR, NF-κB, and mitogen-activated protein kinase (MAPK) pathways.
Importantly, there is no recommendations of any probiotics strain for treatment of Crohn’s disease in
children. Additionally, probiotics definitely seem more favorable for ulcerative colitis, where some
strains have previously confirmed to be effective [15].
3.1.7. Cystic Fibrosis
Intestinal inflammation is a common symptom in patients with cystic fibrosis, in whom bacterial
overgrowth may also be present. Younger patients with cystic fibrosis might be good candidates for
supplementation with probiotics, because their intestinal microbiota is often abnormal due to immense
exposure to antibiotics, suggesting the disturbance of intestinal barrier function and the dysregulation
of innate immune mediators [16]. A prospective randomized, double-blind, placebo-controlled trial
was carried out in 61 children with cystic fibrosis to evaluate Lactobacillus reuteri ATCC55730 in altering
the degree of respiratory exacerbations and of infections of upper respiratory and gastrointestinal
tracts. Pulmonary exacerbations were significantly decreased in the probiotic group. Probiotic and
control groups did not significantly change in the mean number and duration of hospitalizations as a
consequence of pulmonary exacerbations, gastrointestinal infections, fecal calprotectin concentration,
and tested cytokines (TNF-α and IL-8). The authors concluded that probiotic administration attenuates
pulmonary exacerbations in cystic fibrosis patients with mild-to-moderate lung disease, and the
mechanistic speculation of those results was that Lactobacillus strains effect immune responses beyond
the intestinal tract [16].
Based on the complexity of cystic fibrosis, the probiotic treatment requires further and detailed
investigation to ensure a safe therapy.
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Table 2. General probiotic mechanisms of action in NEC.
Reference Animal Species ProbioticStrain/Treatment Type of Study Time Primary Outcome
Good et al., 2014 [68] Newborn mice/premature piglets L. rhamnosus HN001 In vivo and ex vivo 5 days
L. rhamnosus HN001 or its DNA could
protect against the development of NEC
in animals. This seems to require DNA
receptor TLR9 activation
Liu et al., 2012 [72] Newborn rats L. reuteri In vivo and ex vivo 3 days
L. reuteri strains reduced intestinal
inflammation by down-regulating the
IL-6, TNF-α, TLR4, and NF-kB and
up-regulating the IL-10 in rats with NEC
Liu et al., 2010 [71] Newborn rats L. reuteri In vivo and in vitro(IPEC-J2 intestinal cell line) 3 days
L. reuteri reduced the inflammation
caused by LPS in intestinal epithelial
cells and in the ileum
Copeland et al.,
2009 [66] Neonatal rabbit model L. lactis, E. cloacae In vivo 7 days
E. cloacae probiotic fortified diet was
effective by reducing the colonization of
pathogenic bacterium
Foye et al., 2012 [76] Newborn mice L. acidophilus In vivo and in vitro (mouseintestinal epithelial cell line) 7 weeks
L. acidophilus, inulin, or synbiotic
attenuate C. rodentium-induced intestinal
inflammation through NF-κB and Smad
7 expression





L. rhamnosus GG provokes IL-4, IL-10
and urocortin expression and inhibits
LPS-induced TNF-α in trophoblast cells
from human term placenta
Abbreviations: NEC, necrotizing enterocolitis; IL, interleukin; LPS, lipopolysaccharide; NF-κB, nuclear factor κ-B; TNF-α, tumor factor necrosis alpha; TLR, toll-like receptor.
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3.1.8. Other Studies
Recently, our research group has reported different in vitro and in vivo studies related to
probiotics. Thus, we examined the anti-inflammatory properties of probiotics in human DC generated
from CD34+ progenitor cells (hematopoietic stem cells) collected from umbilical cord blood that
showed surface antigens of dendritic Langerhans cells, resembling to the lamina propria DCs in the
intestine [84–86]. We incubated these intestinal-like human DCs with Lactobacillus paracasei CNCM
I-4034, Bifidobacterium breve CNCM I-4035, L. rhamnosus CNCM I-4036 or its cell-free supernatants (CFS),
Salmonella typhi CECT 725, E. coli CECT 742, CECT 515, and CECT 729 or a mixture of these treatments
for 4 h. These probiotic treatments provoked an upregulation of TLR-9, toll-interacting protein,
and CASP8 gene expression. Probiotic supernatants diminished pro-inflammatory cytokines and
chemokines in DCs that were challenged with S. typhi and restored TGF-β levels in the existence of
S. typhi. In addition, supernatants enhanced innate immunity due to the activation of TLR signaling,
especially TLR-9, TLR-2, and TLR-4 gene expression [84–86].
Other results from our research group using an experimental model of obesity in Zucker rats and
in human healthy volunteers who received selected probiotic strains have documented a number of
immunomodulatory effects. Administration of B. breve CNCM I-4035 produced a significant increase
in fecal secretory IgA content. IL-4 and IL-10 were up-regulated, whereas IL-12 was lower in the
serum of subjects after the treatment with any of the three strains. Serum TNF-α levels diminished
in Zucker-Leprfa/fa rats treated with B. breve, L. rhamnosus, or the mixture, whereas L. paracasei
feeding showed a reduction of IL-6 levels in the serum of Zucker-Leprfa/fa rats. Moreover, probiotic
administration downregulated the gene and protein expression of Adamdec1 and Ednrb, and that
of Ptgs1/Cox1 at the gene expression level. This result was partially mediated by a reduction in
both macrophage and dendritic cell populations [21,22,77,87,88]. Additionally, we have studied the
early administration of L. fermentum CECT5716, which is a probiotic strain added in infant formula,
in children. We reported that this probiotic preparation was safe and it did not produce quantifiable
differences in children compared with the control group, but no specific mechanism of action was
addressed [47,89].
In line with our findings, Tsilingiri et al. (2012) have developed an in vitro model system that
offers several physiological characteristics that can be representative of a mucosal microenvironment,
containing the existence of an organized mucus layer and an apical to basolateral polarity. The authors
evaluated the effects of L. paracasei supernatant against S. typhimurium in healthy and IBD tissue [90].
They concluded that probiotics could be more appropriately used in patients in remission and not for
the period of the acute phase of the disease. Additionally, the use of supernatant might be an effective
and safe alternative for the treatment of acute IBD. This effect was observed in the co-incubation
treatment, mediated through the abrogation of TNF-α release without affecting IL-10 secretion [90].
Moreover, in a well-conducted in vitro study, Buccigrossi et al. (2014) have showed the effects of
S. boulardii supernatant in cells infected with rotavirus. The aforementioned supernatant prevents
oxidative stress produced by rotavirus infection, and inhibits chloride secretion in Caco-2 cells [91].
These findings suggest that probiotics and their supernatants can exhibit important molecular effects.
Finally, Figure 1 shows the general probiotic mechanism of action in pediatric intestinal diseases.
Concerning gastrointestinal infections, the most important mechanism of action reported was the
modulation of the immune system. With respect to NEC, the mechanism of actions are related to the
TLR-signaling pathway and the butyric receptor.
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ASC, apoptosis-associated speck-like protein containing a CARD; ERK, extracellular regulated kinase;
IKK, IκB kinase; IL, interleukin; IFN, interferon; IRAK4, IL-1 receptor-associated kinase 4; JNK, Jun
N-terminal kinase; NF-κB, nuclear factor κ-B; NEMO, NF-κB essential modulator; TNF-α, tumor factor
necrosis alpha; TLR, toll-like receptor, TAB1/2/3, TAK binding proteins; TAK1, ubiquitin-dependent
kinase of MKK and IKK; TBK1, serine/threonine-protein kinase 1; TGF, transforming growth factor;
TRAF6, Tumor necrosis factor receptor-associated factor 6.
4. Conclusions
Probiotics and synbiotics have been extensively studied in the evaluation of potential treatments
for different gastrointestinal infections in children, such as acute gastroenteritis, AAD, Clostridium
difficile-associated diarrhea, Helicobacter pylori gastritis, and peptic ulcer, as well as in other intestinal
pathologies associated with gut dysbiosis. It appears that probiotics and synbiotics may be useful
in improving such pathologies, except for AAD and Crohn’s disease. In any case, major adverse
effects of probiotics have since been reported. Although such effects are supported by numerous
clinical studies, further research is required to corroborate the adequate doses and time of treatment.
Some strains, such as L. rhamnosus, have been reported for the treatment of pediatric infections, despite
the existence of other potential probiotics that should be studied. Immune-mediated mechanisms of
action of probiotics include the modulation of both innate and adaptive immunity. However, most of
the reported studies only made speculations and did not attempt to evaluate specific biomarkers of
systemic or intestinal immunity. Only a few in vitro and animal studies have shown that modulation
of the immune system can be mediated through the interaction of probiotics with intestinal TLR, which
in turn affects inflammatory cascade signaling, expression of cytokines and some intestinal host genes
involved in inflammation. Thus, there is a need for designing further studies using probiotics and
synbiotics in pediatric intestinal diseases and addressing their potential mechanisms of action though
appropriate biomarkers of immunity and inflammation to support and provide scientific reasons that
are able to explain the clinical benefits of specific probiotic strains.
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